NERV
Minerva Neurosciences Inc
3.40$
+0.0%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +20.6% | +61.0% | +38.2% | -24.3% | -44.3% | -25.6% | +33.8% | -28.6% | +3.3% | -34.7% | +163.8% | |
| – | +73.1% | +150.5% | +54.5% | -30.5% | -47.6% | -41.8% | +126.7% | -35.4% | +4.6% | -47.0% | +273.2% | |
| – | -23.0% | +480.9% | -68.6% | +92.8% | -57.4% | +18.4% | +139.6% | -40.6% | +13.4% | -47.8% | +285.3% | |
| – | +73.7% | +157.7% | +54.4% | -31.3% | -47.9% | -44.7% | +139.6% | -40.6% | +13.4% | -47.8% | +285.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -39.8% | -63.2% | +428.5% | -34.3% | -52.2% | +535.7% | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | 0.0% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | -55.6% | +0.0% | -99.7% | -16.7% | -60.0% | +87,240,926.6% | – | |
| – | +60.8% | -1.1% | +93.2% | -6.2% | +1.7% | -90.0% | +1,293.1% | +8.6% | +13.6% | -26.4% | +279.9% | |
| – | +51.6% | +82.1% | -29.4% | -47.2% | +83.7% | -52.3% | -10.8% | -51.1% | +142.5% | -15.1% | -19.3% | |
| – | +0.0% | +238.3% | -18.4% | +1,038,988.9% | -100.0% | -35.7% | – | – | – | – | – | |
| – | +112.0% | +7.9% | -2.2% | +25.4% | +28.7% | -57.0% | +86.1% | -47.7% | +86.2% | -10.9% | -60.3% | |
| – | – | -54.8% | -100.0% | – | – | – | – | – | – | – | – | |
| – | +7.4% | +91.6% | +24.2% | -31.4% | -69.2% | +89.6% | -84.9% | -351.1% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +26.0% | +34.6% | +20.4% | +2.3% | +0.6% | +4.9% | +4.4% | +0.0% | +21.8% | +16.4% | +11.8% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.